Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0STMAC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
M9346A Sulfo-SPDB DM4
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 4 Indication(s)
Cervical cancer [ICD11:2C77]
Investigative
Gestational choriocarcinoma [ICD11:2C75]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.8-3.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
Mirvetuximab
|
Antibody Info | ||||
| Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Sulfo-SPDB
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
Soravtansine
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.